Vera Therapeutics, Inc. financial data

Symbol
VERA on Nasdaq
Location
2000 Sierra Point Parkway, Suite 1200, Brisbane, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.91K % +15.7%
Debt-to-equity 19.3 % -28.2%
Return On Equity -50.9 % -1.56%
Return On Assets -42.7 % -8.03%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.9M shares +0.96%
Entity Public Float 1.7B USD +278%
Common Stock, Value, Issued 64K USD +16.4%
Weighted Average Number of Shares Outstanding, Basic 63.8M shares +16.3%
Weighted Average Number of Shares Outstanding, Diluted 63.8M shares +16.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 189M USD +66.6%
General and Administrative Expense 80.9M USD +155%
Operating Income (Loss) -270M USD -86%
Nonoperating Income (Expense) 18.2M USD +67.2%
Net Income (Loss) Attributable to Parent -252M USD -87.5%
Earnings Per Share, Basic -3 USD/shares -55.3%
Earnings Per Share, Diluted -3 USD/shares -55.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 57.8M USD +112%
Marketable Securities, Current 440M USD +34.8%
Other Assets, Current 1.15M USD +1.77%
Assets, Current 511M USD +40.4%
Property, Plant and Equipment, Net 1.16M USD +214%
Operating Lease, Right-of-Use Asset 2.04M USD -48.1%
Assets 518M USD +40.4%
Accounts Payable, Current 18M USD +290%
Employee-related Liabilities, Current 9.72M USD +167%
Accrued Liabilities, Current 23.5M USD +17.3%
Liabilities, Current 41.9M USD +58.3%
Operating Lease, Liability, Noncurrent 2.1M USD -18.4%
Liabilities 119M USD +49.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 881K USD -15.6%
Retained Earnings (Accumulated Deficit) -670M USD -60.3%
Stockholders' Equity Attributable to Parent 399M USD +38%
Liabilities and Equity 518M USD +40.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.4M USD -60.8%
Net Cash Provided by (Used in) Financing Activities 1.53M USD -99.4%
Net Cash Provided by (Used in) Investing Activities 15.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -37.6M USD -260%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 57.8M USD +112%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.58M USD +4.01%
Deferred Tax Assets, Valuation Allowance 107M USD +49.7%
Deferred Tax Assets, Gross 108M USD +49.3%
Operating Lease, Liability 2.57M USD
Payments to Acquire Property, Plant, and Equipment 187K USD
Lessee, Operating Lease, Liability, to be Paid 3.22M USD -47.1%
Operating Lease, Liability, Current 473K USD -74.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 966K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 830K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +33%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 656K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 995K USD
Deferred Tax Assets, Operating Loss Carryforwards 38.7M USD +40.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.05M USD +35.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 254K USD
Operating Lease, Payments 634K USD -17%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 85K USD +673%
Deferred Tax Assets, Net of Valuation Allowance 792K USD +10.2%
Share-based Payment Arrangement, Expense 33.2M USD +86.3%
Interest Expense 5.82M USD +130%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%